<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02968212</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-5401</org_study_id>
    <nct_id>NCT02968212</nct_id>
  </id_info>
  <brief_title>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</brief_title>
  <official_title>Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at Tyler</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine&#xD;
      when used to treat Mycobacteria avium complex (MAC) lung disease.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in&#xD;
      the United States. It is approved for the treatment of Mycobacterium leprae (leprosy)&#xD;
      infections. Clofazimine has been used for many years off-label against other Mycobacterium,&#xD;
      including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent infection&#xD;
      in older Americans. The U.S. Food and Drug Administration currently oversees clofazimine use&#xD;
      to treat MAC lung disease through a special investigational drug access program. However, to&#xD;
      date, there is little understanding of the benefits and risks of clofazimine when used to&#xD;
      treat MAC lung disease. Accordingly, the investigators have developed a randomized,&#xD;
      placebo-controlled clinical trial to assess the clinical efficacy and safety of clofazimine.&#xD;
      To be eligible, participants must have MAC lung disease, positive sputum cultures for MAC,&#xD;
      and not currently taking antibiotics for MAC. Eligible participants (102 total enrolled) will&#xD;
      be randomly given either clofazimine or placebo for 6 months, and followed closely by their&#xD;
      treating physician. The percentage of participants who become culture negative in each group&#xD;
      will be compared, as it is suspected that participants treated with clofazimine will be more&#xD;
      likely to become culture negative. The safety of clofazimine will be measured as well as&#xD;
      other potential benefits of the therapy including changes in lung function and quality of&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline sputum culture at 24 weeks</measure>
    <time_frame>Sputum examined for culture change from Baseline at 24 weeks</time_frame>
    <description>sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline 6 Minute Walk Test at 24 weeks</measure>
    <time_frame>6 Minute Walk Test results examined for change from Baseline at 24 weeks</time_frame>
    <description>Walking distance achieved in 6 minutes is assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline PROMIS Fatigue 7a short form questionnaire at 24 weeks</measure>
    <time_frame>PROMIS Fatigue 7a short form results examined for change from Baseline at 24 weeks</time_frame>
    <description>Self-administered questionnaire assessing a range of self-reported symptoms over the past seven days, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Quality of Life-Bronchiectasis (QOL-B) with NTM module at 24 weeks</measure>
    <time_frame>QOL-B results examined for change from Baseline at 24 weeks</time_frame>
    <description>Self-administered questionnaire measuring 8 separate domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline CT scan at 24 weeks</measure>
    <time_frame>CT scan examined for change from Baseline at 24 weeks</time_frame>
    <description>CT scans will be computationally evaluated using custom software to provide volumetric assessment of NTM-associated abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline semi-quantitative sputum acid fast smear culture at 24 weeks</measure>
    <time_frame>semi-quantitative sputum acid fast smear culture examined for change from Baseline at 24 weeks</time_frame>
    <description>sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Spirometry at 24 weeks</measure>
    <time_frame>Spirometry with FEV1/FVC ratio examined for change from Baseline at 24 weeks</time_frame>
    <description>Mean change in pulmonary function parameters as measured by %predicted FEV1 and FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Erythrocyte Sedimentation Rate at 24 weeks</measure>
    <time_frame>Erythrocyte Sedimentation Rate examined for change from Baseline at 24 weeks</time_frame>
    <description>Detecting change in Inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline C-Reactive Protein levels at 24 weeks</measure>
    <time_frame>C-Reactive Protein levels examined for change from Baseline at 24 weeks</time_frame>
    <description>Detecting change in Inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Number of Patient-reported and Investigator-reported Adverse Events at 24 weeks</time_frame>
    <description>Comparison of experienced adverse events between the two study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline QT interval at 24 weeks</measure>
    <time_frame>QT interval examined for change from Baseline at 24 weeks</time_frame>
    <description>A 12-lead ECG will be conducted, and the QT interval calculated using Fridericia's formula: QTC = QT / RR 1/3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline blood serum chemistry at week 24</measure>
    <time_frame>blood serum chemistry examined for change from Baseline at 24 weeks</time_frame>
    <description>Detecting changes in liver ALT and AST levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline complete blood count at week 24</measure>
    <time_frame>complete blood count examined for change from Baseline at 24 weeks</time_frame>
    <description>Detecting changes in complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Minimal Inhibitory Concentration of MAC isolates in vitro at week 24</measure>
    <time_frame>Minimal Inhibitory Concentration of MAC isolates in vitro examined for change from Baseline at 24 weeks</time_frame>
    <description>Detecting change in MAC isolates sensitivity to clofazimine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Mycobacterium Avium Complex</condition>
  <arm_group>
    <arm_group_label>clofazimine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lamprene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.</description>
    <arm_group_label>clofazimine</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 2 positive MAC sputum cultures in the last 12 months with at least one&#xD;
             obtained within 12 weeks prior to randomization&#xD;
&#xD;
          -  Meet ATS/IDSA 2007 pulmonary disease criteria&#xD;
&#xD;
          -  Adult males and females age 18 or over&#xD;
&#xD;
          -  Ability to provide informed consent for the use of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who is unwilling or unable to provide consent or to comply with this&#xD;
             protocol&#xD;
&#xD;
          -  Cavitary NTM disease&#xD;
&#xD;
          -  Patients who are currently taking or within the prior 12 weeks received any of the&#xD;
             following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy&#xD;
             (macrolide, ethambutol, rifampin) for MAC&#xD;
&#xD;
          -  Current usage of inhaled amikacin, tobramycin, or gentamicin&#xD;
&#xD;
          -  In the judgment of the investigator, the patient is not a candidate for observation&#xD;
             (e.g. severe symptoms, extensive disease burden) but rather should be treated with&#xD;
             standard multi-drug therapy&#xD;
&#xD;
          -  Prior use of clofazimine that has resulted in an allergy to clofazimine or a severe&#xD;
             adverse reaction&#xD;
&#xD;
          -  Current usage of medications associated with QT prolongation (see Appendix C for full&#xD;
             list of prohibited concomitant medications)&#xD;
&#xD;
          -  Corrected QT (QTc) interval on electrocardiogram (ECG) &gt; 470 ms for females or 450 ms&#xD;
             for males, calculated using Fridericia's formula60,61&#xD;
&#xD;
          -  Advanced lung disease (FEV&lt;30%)&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Active pulmonary tuberculosis requiring treatment at screening&#xD;
&#xD;
          -  Active pulmonary malignancy or chemotherapy or radiation within 1 year of screening&#xD;
&#xD;
          -  Use of chronic systemic corticosteroids at doses of 15 mg/day for more than 12 weeks&#xD;
&#xD;
          -  Prior lung or other solid organ transplant&#xD;
&#xD;
          -  Pregnancy, or breastfeeding that will continue during treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amanda Brunton, MPH</last_name>
    <phone>503-494-6327</phone>
    <email>brunton@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haley Miller</last_name>
    <phone>503-346-1548</phone>
    <email>millehal@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Harris, MBA-MHA, DHA</last_name>
      <phone>813-250-2392</phone>
      <email>trharris1@usf.edu</email>
    </contact>
    <investigator>
      <last_name>W. Dwight Miller, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Rohert</last_name>
      <phone>504-568-2248</phone>
      <email>orohre@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Juzar Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Heart, Lung and Blood Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Debacker</last_name>
      <phone>503-346-3435</phone>
      <email>debacken@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gina Megson, MPH</last_name>
      <phone>(503) 494-2565</phone>
      <email>megson@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin L Winthrop, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E Griffith, MD</last_name>
    </contact>
    <investigator>
      <last_name>David E Griffith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>March 31, 2023</last_update_submitted>
  <last_update_submitted_qc>March 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kevin Winthrop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Mycobacterium avium Complex</keyword>
  <keyword>Clofazimine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02968212
org study id: FD-R-5401
nct id: NCT02968212
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine
      when used to treat Mycobacteria avium complex (MAC) lung disease.

      Funding Source - FDA OOPD
Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in
      the United States. It is approved for the treatment of Mycobacterium leprae (leprosy)
      infections. Clofazimine has been used for many years off-label against other Mycobacterium,
      including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent infection
      in older Americans. The U.S. Food and Drug Administration currently oversees clofazimine use
      to treat MAC lung disease through a special investigational drug access program. However, to
      date, there is little understanding of the benefits and risks of clofazimine when used to
      treat MAC lung disease. Accordingly, the investigators have developed a randomized,
      placebo-controlled clinical trial to assess the clinical efficacy and safety of clofazimine.
      To be eligible, participants must have MAC lung disease, positive sputum cultures for MAC,
      and not currently taking antibiotics for MAC. Eligible participants (102 total enrolled) will
      be randomly given either clofazimine or placebo for 6 months, and followed closely by their
      treating physician. The percentage of participants who become culture negative in each group
      will be compared, as it is suspected that participants treated with clofazimine will be more
      likely to become culture negative. The safety of clofazimine will be measured as well as
      other potential benefits of the therapy including changes in lung function and quality of
      life.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Change from Baseline sputum culture at 24 weeks
time frame: Sputum examined for culture change from Baseline at 24 weeks
description: sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.
measure: Change from Baseline 6 Minute Walk Test at 24 weeks
time frame: 6 Minute Walk Test results examined for change from Baseline at 24 weeks
description: Walking distance achieved in 6 minutes is assessed
measure: Change from Baseline PROMIS Fatigue 7a short form questionnaire at 24 weeks
time frame: PROMIS Fatigue 7a short form results examined for change from Baseline at 24 weeks
description: Self-administered questionnaire assessing a range of self-reported symptoms over the past seven days, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities.
measure: Change from Baseline Quality of Life-Bronchiectasis (QOL-B) with NTM module at 24 weeks
time frame: QOL-B results examined for change from Baseline at 24 weeks
description: Self-administered questionnaire measuring 8 separate domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms.
measure: Change from Baseline CT scan at 24 weeks
time frame: CT scan examined for change from Baseline at 24 weeks
description: CT scans will be computationally evaluated using custom software to provide volumetric assessment of NTM-associated abnormalities.
measure: Change from Baseline semi-quantitative sputum acid fast smear culture at 24 weeks
time frame: semi-quantitative sputum acid fast smear culture examined for change from Baseline at 24 weeks
description: sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.
measure: Change from Baseline Spirometry at 24 weeks
time frame: Spirometry with FEV1/FVC ratio examined for change from Baseline at 24 weeks
description: Mean change in pulmonary function parameters as measured by %predicted FEV1 and FVC
measure: Change from Baseline Erythrocyte Sedimentation Rate at 24 weeks
time frame: Erythrocyte Sedimentation Rate examined for change from Baseline at 24 weeks
description: Detecting change in Inflammatory markers
measure: Change from Baseline C-Reactive Protein levels at 24 weeks
time frame: C-Reactive Protein levels examined for change from Baseline at 24 weeks
description: Detecting change in Inflammatory markers
measure: Number of Adverse Events
time frame: Number of Patient-reported and Investigator-reported Adverse Events at 24 weeks
description: Comparison of experienced adverse events between the two study groups
measure: Change from Baseline QT interval at 24 weeks
time frame: QT interval examined for change from Baseline at 24 weeks
description: A 12-lead ECG will be conducted, and the QT interval calculated using Fridericia's formula: QTC = QT / RR 1/3
measure: Change from Baseline blood serum chemistry at week 24
time frame: blood serum chemistry examined for change from Baseline at 24 weeks
description: Detecting changes in liver ALT and AST levels
measure: Change from Baseline complete blood count at week 24
time frame: complete blood count examined for change from Baseline at 24 weeks
description: Detecting changes in complete blood count
measure: Change from Baseline Minimal Inhibitory Concentration of MAC isolates in vitro at week 24
time frame: Minimal Inhibitory Concentration of MAC isolates in vitro examined for change from Baseline at 24 weeks
description: Detecting change in MAC isolates sensitivity to clofazimine
arm group label: clofazimine
arm group type: Experimental
description: Participants receive lamprene
arm group label: sugar pill
arm group type: Placebo Comparator
description: Participants receive placebo
intervention type: Drug
intervention name: Clofazimine
description: All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
arm group label: clofazimine
other name: Lamprene
intervention type: Other
intervention name: sugar pill
description: All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
arm group label: sugar pill
other name: placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Amanda Brunton, MPH
phone: 503-494-6327
email: brunton@ohsu.edu
last name: Haley Miller
phone: 503-346-1548
email: millehal@ohsu.edu
facility: 
status: Completed
facility: 
status: Withdrawn
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Completed
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Active, not recruiting
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Withdrawn
facility: 
status: Recruiting
contact: 
investigator: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Oregon Health and Science University
investigator full name: Kevin Winthrop
investigator title: Professor
mesh term: Mycobacterium Infections
mesh term: Mycobacterium avium-intracellulare Infection
mesh term: Clofazimine
sharing ipd: No